Andrew Holt, MD
Pulmonary Disease · Memphis, TNNPI 1316367071
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,180 of the $69,268 with a category attached, or 84.0%. AstraZeneca accounts for 89.6% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $44,013, more than ten times the $15 reported in 2019. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $333.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$62K
- Actelion Pharmaceuticals US, Inc.$4K
- ALON Medical Technology$1K
- United Therapeutics Corporation$868
- GSK$357
- Sanofi$175
- plus $895 from 13 others
What the payments were for
- Consulting fees$3,6285%
- Speaking & faculty fees$58,18084%
- Travel & lodging$1,0862%
- Food & beverage$4,9497%
- Education$1,4252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $62,075 |
| Actelion Pharmaceuticals US, Inc. | 52 | $3,698 |
| ALON Medical Technology | 1 | $1,200 |
| United Therapeutics Corporation | 25 | $868 |
| GSK | 10 | $357 |
| Sanofi | 4 | $175 |
| Lungpacer Medical USA Inc | 1 | $174 |
| Bayer | 7 | $162 |
| Boehringer Ingelheim | 9 | $127 |
| Insmed, Inc. | 5 | $117 |
| Merck | 3 | $52 |
| AbbVie | 3 | $51 |
| Pfizer | 3 | $49 |
| Amgen | 2 | $33 |
| Grifols USA, LLC | 2 | $33 |
| La Jolla Pharmaceutical Company | 2 | $31 |
| Harmony Biosciences LLC | 2 | $31 |
| Genentech USA, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,268 in reported general payments places this provider in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 21 | $462,265 |
| OpsumitMacitentan | 38 | $453,992 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $57,160 |
| Dupixent PenDupilumab | 15 | $54,395 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,106 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,877 |
| Spiriva RespimatTiotropium Bromide | 20 | $10,828 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,139 |
| Ethambutol Hcl | 16 | $1,956 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,014 |
| Rifampin | 14 | $850 |
| Azithromycin | 36 | $791 |
| Sildenafil Citrate | 14 | $577 |
| Montelukast Sodium | 24 | $315 |
| Fluticasone Propionate | 27 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $3,698 | $916,25759 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $357 | $79,143126 claims |
| Boehringer IngelheimSpiriva Respimat | $127 | $10,82820 claims |
| AstraZenecaBreztri Aerosphere | $62,075 | $9,13915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Memphis
- Dipen KadariaMemphis$31K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.